{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T20:14:47Z","timestamp":1773173687237,"version":"3.50.1"},"reference-count":22,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T00:00:00Z","timestamp":1600905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Cetuximab is an anti\u2010epidermal growth factor receptor mouse\u2010human chimeric monoclonal antibody used to treat advanced colorectal cancers. Initial data suggest that severe infusion reactions occurred in 4.5%, many on first exposure. The majority of those with anaphylactic reactions possess predeveloped IgE antibodies to galactose\u2010alpha\u20101,3\u2010galactose. It is thought that the vector for preexposure to alpha\u2010gal is antigen inoculation via tick bites. This retrospective study reviews the experience of two community cancer centers in high tick exposure areas in Sydney with cetuximab anaphylaxis and proposes a protocol to avoid this.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Severe cetuximab infusion reactions occurring in the Northern Cancer Institute Frenchs Forest and St Leonards clinics, Sydney, from May 2014 to February 2019 were recorded. Area of residence was then compared to areas of known high tick prevalence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 87 patients received cetuximab in this period. Six patients (6.9%) experienced at least a grade 3 reaction, three females, age range 41\u201372 years (median 57.5 years). All were receiving cetuximab for metastatic colorectal cancer and their anaphylaxis occurred with the first infusion in all cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These cases support the existing theory of increased rates of cetuximab anaphylaxis in areas of high tick prevalence. Given this, we recommend the following protocol for patients being considered for cetuximab therapy: known mammalian meat allergy as an absolute contraindication; all patients receiving cetuximab should have RAST (ImmunoCAP<jats:sup>\u00ae<\/jats:sup>) testing for alpha\u2010gal specific\u2010IgE\u2010specific antibodies before first infusion and those who test positive to be considered alternate therapy.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajco.13465","type":"journal-article","created":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T19:06:36Z","timestamp":1600974396000},"page":"448-453","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Increased rates of cetuximab reactions in tick prevalent regions and a proposed protocol for risk mitigation"],"prefix":"10.1111","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7242-0528","authenticated-orcid":false,"given":"Alexander","family":"Yuile","sequence":"first","affiliation":[{"name":"Northern Cancer Institute  Sydney New South Wales Australia"},{"name":"Royal North Shore Hospital  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Fanuli","sequence":"additional","affiliation":[{"name":"Northern Cancer Institute  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheryl","family":"van Nunen","sequence":"additional","affiliation":[{"name":"Northern Cancer Institute  Sydney New South Wales Australia"},{"name":"Royal North Shore Hospital  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Connie","family":"Diakos","sequence":"additional","affiliation":[{"name":"Northern Cancer Institute  Sydney New South Wales Australia"},{"name":"Royal North Shore Hospital  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Clarke","sequence":"additional","affiliation":[{"name":"Northern Cancer Institute  Sydney New South Wales Australia"},{"name":"Royal North Shore Hospital  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Steiner","sequence":"additional","affiliation":[{"name":"Northern Cancer Institute  Sydney New South Wales Australia"},{"name":"Royal North Shore Hospital  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robyn","family":"MacMillan","sequence":"additional","affiliation":[{"name":"Northern Cancer Institute  Sydney New South Wales Australia"},{"name":"Royal North Shore Hospital  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meredith","family":"Oatley","sequence":"additional","affiliation":[{"name":"Northern Cancer Institute  Sydney New South Wales Australia"},{"name":"Royal North Shore Hospital  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Pavlakis","sequence":"additional","affiliation":[{"name":"Northern Cancer Institute  Sydney New South Wales Australia"},{"name":"Royal North Shore Hospital  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,9,24]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"Merk Erbitux production information version A016\u20101019."},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa071834"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa074943"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.7812"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.02.019"},{"key":"e_1_2_12_7_1","first-page":"A132","article-title":"The association between Ixodes holocyclus tick bite reactions and red meat allergy","volume":"39","author":"Nunen S","year":"2009","journal-title":"Intern Med J"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.12.1947"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cia2.12016"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29978"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja17.00591"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.10.052"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0707-z"},{"key":"e_1_2_12_14_1","first-page":"bcr0220125797","article-title":"Hypersensitivity reaction to human papillomavirus vaccine due to polysorbate 80","volume":"8","author":"Badiu I","year":"2012","journal-title":"BMJ Case Rep"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.126460"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29978"},{"key":"e_1_2_12_17_1","first-page":"16","article-title":"Life\u2010threatening cetuximab anaphylaxis: cautionary tales and possible IgE consumption during a drug\u2010induced anaphylaxis","volume":"49","author":"Lauer S","year":"2019","journal-title":"Intern Med J"},{"issue":"106","key":"e_1_2_12_18_1","first-page":"376","article-title":"Sensitisation and sero\u2010reversion to tick\u2010bite induced galactose\u2010alpha\u20101,3\u2010galactose, meat and dairy sensitisation in New South Wales, Australia","volume":"74","author":"Baumgart K","year":"2019","journal-title":"Allergy"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.5415\/apallergy.2018.8.e31"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24945"},{"key":"e_1_2_12_21_1","volume-title":"The specificity of serological reactions","author":"Landsteiner K","year":"1936"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2007.01.023"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055566"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.13465","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajco.13465","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.13465","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T11:33:41Z","timestamp":1693222421000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.13465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,24]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1111\/ajco.13465"],"URL":"https:\/\/doi.org\/10.1111\/ajco.13465","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,24]]},"assertion":[{"value":"2020-05-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}